FLC
CYTK icon

Fifth Lane Capital’s Cytokinetics CYTK Stock Holding History

Fifth Lane Capital’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-8,000
Closed -$440K – 126
2025
Q3 		$440K Sell
8,000
-1,000
-11% -$41.2K 0.44% 47
2025
Q2 		$297K Buy
+9,000
New +$313K 0.36% 39
2025
Q1 		– Sell
-6,000
Closed -$282K – 37
2024
Q4 		$282K Buy
6,000
+2,000
+50% +$104K 0.83% 18
2024
Q3 		$211K Buy
+4,000
New +$223K 0.53% 25

Other funds holding CYTK

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Fifth Lane Capital's CYTK Position: Q4 2025 in Review

Fifth Lane Capital sold out of Cytokinetics (CYTK) in Q4 2025, closing a stake of 8,000 shares — an estimated $440K sold.

Fifth Lane Capital first reported a position in CYTK in Q3 2024 and held it in 4 quarters. The position peaked at $440K in Q3 2025. 430 funds tracked by Wall St. Rank hold CYTK as of Q4 2025.

  • Fifth Lane Capital reported no remaining Cytokinetics position as of Q4 2025 after selling out during the quarter.
  • Fifth Lane Capital sold 8,000 Cytokinetics shares in Q4 2025, an estimated $440K.
  • Fifth Lane Capital first reported a position in Cytokinetics in Q3 2024 and held it in 4 quarters.
  • Fifth Lane Capital's Cytokinetics position peaked at $440K in Q3 2025.
  • 430 funds tracked by Wall St. Rank held Cytokinetics as of Q4 2025.

Based on Fifth Lane Capital's 13F filing for Q4 2025, filed 13 Feb 2026.